Mylotarg (Gemtuzumab Ozogamicin)

gemtuzumab ozogamicin, the active ingredient in Mylotarg, is a monoclonal antibody presented as a lyophilized powder for intravenous infusion for intravenous use. It treats acute myeloid leukemia in adult and pediatric patients, targeting CD33‑positive leukemic cells to improve remission outcomes.

GNH USA supplies Mylotarg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory‑approved product documentation for global distribution. Clients receive dedicated technical support and cold‑chain logistics to maintain product integrity during shipment.

Mylotarg is a CD33‑targeted monoclonal antibody used in the treatment of acute myeloid leukemia. - Newly diagnosed CD33‑positive acute myeloid leukemia: used in combination with standard chemotherapy to increase remission rates. - Relapsed or refractory acute myeloid leukemia: administered as monotherapy or with other agents to achieve disease control. - Pediatric acute myeloid leukemia (age ≥1 year): incorporated into specific protocols to improve outcomes in children.

Mylotarg may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Infusion‑related reactions such as fever, chills, or hypotension. - Nausea and vomiting. - Fatigue or general weakness. - Cytopenias, including neutropenia and thrombocytopenia.

Serious or Rare Side Effects: - Veno‑occlusive disease (VOD) of the liver. - Severe hemorrhage or bleeding complications. - Anaphylaxis or severe allergic reactions.

When using Mylotarg, clinicians should observe several precautionary measures to minimize risk. - Pregnancy: category B; use only if the potential benefit justifies the potential risk to the fetus. - Hepatic function: monitor liver enzymes and signs of VOD before and during therapy. - Bleeding risk: assess coagulation status and avoid concurrent anticoagulant excess. - Infection risk: monitor for febrile neutropenia and provide appropriate antimicrobial prophylaxis. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mylotarg can interact with other medicines; awareness of the interaction level guides clinical management.

Major Interactions (Avoid): - Concurrent use with other hepatotoxic agents may increase the risk of liver injury. - Combination with additional CD33‑targeted therapies can lead to additive toxicity.

Moderate Interactions (Monitor Closely): - Anticoagulants: may exacerbate bleeding tendencies. - Other myelosuppressive chemotherapy: can intensify cytopenias. - Live vaccines: heightened risk of infection; consider deferral during treatment.